Tune Therapeutics

Executive Summary

Tune Therapeutics is pioneering next-generation epigenetic editing with its TEMPO platform, which modulates gene expression without cutting DNA. By writing programmable epigenetic marks via CRISPR-based targeting, the company aims to precisely activate or repress genes, offering advantages over traditional gene editing in safety and reversibility. Initially focused on oncology and genetic diseases, Tune has raised $175M since its 2021 founding, signaling strong investor confidence. The platform's potential to address hard-to-treat conditions positions it as a leader in the emerging epigenetic therapy space, though it remains in preclinical stages with no pipelines disclosed yet.

Upcoming Catalysts (preview)

• Q1 2027IND filing for lead oncology program40% success
• Q4 2026Presentation of preclinical data at major conference70% success
• Q2 2027Strategic partnership or licensing deal for genetic disease program50% success